Generics Bulletin | ジェネリック医薬品＆バイオシミラーニュース | インフォーマ・ファーマインテリジェンス

日本国内では2020年9月までにジェネリック医薬品の使用割合を80％にする目標を挙げています。このような中、Generics Bulletinはグローバルな専門アナリスト＆ジャーナリストの広範なネットワークを駆使して、世界中の市場動向を追跡することで、貴重なニュースを提供しています。また、市場プレーヤーのトップエグゼクティブやオピニオンリーダーのインタビューなども定期的に掲載しています。

深い専門性と具体的なデータに基づいたニュースレポートは、世界の大手ジェネリック医薬品メーカーの戦略を明らかにし、その計画、ポートフォリオ、業績を分析＆報告します。

Generics Bulletinでは以下のトピックをカバーしています。

規制・コンプライアンスの変更
法規制の進展
競合製品の開発
合併・買収活動
新製品の発売
マーケティングの課題
広告戦略など

1週間無料トライアル

Generics Bulletin: ジェネリック＆バイオシミラーニュース

EU Reforms Must Heed Pandemic Lessons

Reforms set out by the European Commission to better prepare the EU for future health crises must heed key lessons learned from experiences of the COVID-19 pandemic, such as the benefits of digitalization, Medicines for Europe has urged.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Glenmark Debuts Favipiravir For COVID-19 In India

Glenmark has received the go-ahead in India for and launched its low-priced favipiravir product for mild to moderate COVID-19 under an accelerated approval process.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Generics Industry Experiences Extraordinary First Quarter Due To COVID-19 Crisis

Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

EU Sees Drug Shortage Risk From COVID-19 Second Wave

A second wave of COVID-19 infection later this year would put even greater pressure on drugs used in patients hospitalized with serious respiratory problems, a new report warns.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

European Industry Played Key Role In Mitigating COVID-19

In the first part of an exclusive two-part interview, James Burt – Accord’s executive vice-president for Europe, the Middle East and North Africa – talks to Generics Bulletin about the key actions taken by the generics industry to mitigate the coronavirus pandemic, and the changed landscape that the off-patent arena can expect to see in future.

Biomedtracker: 開発中医薬品をFDA承認確率で評価, Trialtrove: 医療用医薬品の臨床試験情報デ...

COVID-19 Infographic

Access the infographic below which explores the number of treatment drugs for COVID-19 currently in clinical trials or in development, events including progress updates, partnerships, regulatory and trial announcements etc, and the number of articles published on COVID-19 as of March 3, 2020. This data has been tracked and reported via Informa Pharma Intelligence’s clinical, regulatory and commercial data and analytics, and news and insight tools including Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet, Medtech Insight, and Generics Bulletin etc.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Coherus Is Confident After US Ranibizumab Filing

Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Celltrion's Remsima SC Ready For Early 2020 Launch

Celltrion says it is ready to roll out its Remsima SC subcutaneous infliximab in Europe in the first quarter of 2020, after receiving a formal pan-European marketing authorization from the European Commission.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

California Plans To Create Own Generics Label

California’s 2020-2021 fiscal budget includes plans to work with manufacturers to establish the state’s own generics label. But industry is sceptical that the initiative will deliver the savings that the US state hopes for.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Biocon’s Malaysia Insulin Facility Hit With 12 FDA Observations

The US FDA has slapped Biocon with a dozen observations over three units at its insulin manufacturing facility in Malaysia, but the Indian biotech firm says the problems can be remedied quickly and that US launch plans are on track for its insulin product glargine challenging French drug-maker Sanofi’s multi-billion-dollar Lantus.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Biocon Biologics Gets True North Investment

Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Alberta Is Second Canadian Province To Switch To Biosimilars

Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Pfizer Reports 80% Biosimilars Growth In Q3

Pfizer has reported 80% growth in its global biosimilars business for the third quarter of 2020, on the back of recent oncology launches. Though the company’s sterile injectables saw a slight drop in business, Pfizer’s biopharma business saw 4% growth.

HBW Insight : コンシューマーヘルスケア産業のニュース, Generics Bulletin: ジェネリック...

Pharma Intelligence Launches Alexa Skill

Keep up with topics you care about in Pharma and Medtech with the new Alexa Skill from Informa Pharma Intelligence. Access daily news briefings to stay up to date with the latest news, right from your Alexa smartphone app!

Generics Bulletin: ジェネリック＆バイオシミラーニュース

EMA Endorses Dexamethasone For COVID-19

Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.

Generics Bulletin: ジェネリック＆バイオシミラーニュース

ジェネリック医薬品、バイオシミラーの情報源として

このサービスの特徴

Below are the Feature List

世界のジェネリック＆ バイオシミラーを把握

国際競争力を強化する独自のニュースと分析

オンラインでアクセスできるから簡単＆便利

ジャーナリスト＆アナ リストがご質問に回答

無料の最新記事＆レポート

医薬品ニュースサービス・ヘッドライン

医薬品産業専門のジャーナリスト＆アナリスト

Below are the Analyst Profile

Aidan Fry

Editor, Executive Editor, Commercial/R&D

Duncan Emerton

Consultant, Director Pharma Consulting

Andrea Charles

Editor, Editor, Custom Content

無料トライアル＆お問い合わせ

This is Contactus Section

無料トライアルお申込み

お問い合わせ先

レポートストア

世界のジェネリック＆バイオシミラーを把握

ジャーナリスト＆アナリストがご質問に回答